Citrate therapy for calcium phosphate stones

Area of Science:

• Nephrology
• Urology
• Biochemistry

Background:

• Calcium phosphate (CaP) stones are a growing cause of recurrent kidney stones.
• Current treatments for CaP stones are often ineffective.
• Low urinary citrate levels (hypocitraturia) are a known risk factor for CaP stone formation.

Purpose of the Study:

• To review the role of citrate therapy in managing calcium phosphate nephrolithiasis.
• To explore the mechanisms by which citrate inhibits CaP stone formation.
• To evaluate the clinical effectiveness of citrate in preventing CaP stone recurrence.

Main Methods:

• Review of existing literature on citrate therapy and CaP nephrolithiasis.
• Analysis of in-vitro studies on citrate's effect on CaP crystal growth.
• Examination of clinical data on the impact of different citrate formulations.

Main Results:

• Citrate inhibits CaP stone formation via multiple mechanisms, including complexation with calcium and inhibition of nucleation, growth, and aggregation.
• In-vitro studies show citrate significantly retards CaP crystal growth, with mechanisms varying by concentration and supersaturation.
• Potassium citrate increases urinary citrate and reduces calcium excretion but may elevate urine pH; citric acid has minimal impact.

Conclusions:

• Citrate demonstrates significant in-vitro potential to inhibit calcium phosphate crystal growth.
• The clinical impact of citrate therapy on CaP stone recurrence, particularly concerning alkali load effects, needs further research.